The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M., van de Rijn, M., Jeffrey, S., et al. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.191367098 · Cited by 11,695 · see citing works

Gene expression profiling predicts clinical outcome of breast cancer

van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · see citing works

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,363 · see citing works

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1

Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069 · see citing works

Multidrug resistance in cancer: role of ATP–dependent transporters

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · see citing works

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works

The resurgence of platinum-based cancer chemotherapy

Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

The DNA Damage Response: Making It Safe to Play with Knives

Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · see citing works

Identification of the breast cancer susceptibility gene BRCA2

Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645 · see citing works

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · see citing works

A decade of exploring the cancer epigenome—biological and translational implications

Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · see citing works

The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer

Fishel, R. A., Lescoe, M. K., Rao, M. R. S., Copeland, N. G., Jenkins, N. A., Garber, J. E., Kane, M., & Kolodner, R. D. (1993) · Cell · doi:10.1016/0092-8674(93)90546-3 · Cited by 2,857 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

Ionov, Y., Peinado, M. A., Malkhosyan, S. R., Shibata, D. K., & Perucho, M. (1993) · Nature · doi:10.1038/363558a0 · Cited by 2,707 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works

Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer

Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R. E., Peltomäki, P., Sistonen, P., Aaltonen, L. A., Nyström, M., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90330-s · Cited by 2,271 · see citing works

Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents

Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256 · see citing works

The first 30 years of p53: growing ever more complex.

Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works

Mutation of a mutL Homolog in Hereditary Colon Cancer

Papadopoulos, N., Nicolaides, N. C., Wei, Y.-F., Ruben, S. M., Carter, K. C., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C. M., Adams, M. D., et al. (1994) · Science · doi:10.1126/science.8128251 · Cited by 1,822 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Olaussen, K. A., Dunant, A., Fouret, P. J., Brambilla, E. M., André, F., Haddad, V., Clermont, E., Filipits, M., Pirker, R., Popper, H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,725 · see citing works

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671 · see citing works

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655 · see citing works

Hallmarks of 'BRCAness' in sporadic cancers

Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,651 · see citing works

Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6

Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., Gellon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M. M., et al. (2006) · Cell · doi:10.1016/j.cell.2005.11.044 · Cited by 1,637 · see citing works

Chk1 is an essential kinase that is regulated by Atr and required for the G ₂ /M DNA damage checkpoint

Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes &amp; Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625 · see citing works

Chk1 and Chk2 kinases in checkpoint control and cancer

Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2

Hirao, A., Kong, Y., Matsuoka, S., Wakeham, A. C., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., & Mak, T. W. (2000) · Science · doi:10.1126/science.287.5459.1824 · Cited by 1,288 · see citing works

Brca1 Controls Homology-Directed DNA Repair

Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245 · see citing works

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086 · see citing works

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · see citing works

BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks

Moynahan, M. E., Pierce, A. J., & Jasin, M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00174-5 · Cited by 1,007 · see citing works

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001 · see citing works

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 954 · see citing works

Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications

Lynch, H. T., Lynch, P. M., Lanspa, S. J., Snyder, C., Lynch, J. F., & Boland, C. R. (2009) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01230.x · Cited by 842 · see citing works

Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability

Liu, B., Nicolaides, N. C., Markowitz, S. D., Willson, J. K. V., Parsons, R. E., Jen, J., Papadopolous, N., Peltomäki, P., de la Chapelle, A., Hamilton, S. R., et al. (1995) · Nature Genetics · doi:10.1038/ng0195-48 · Cited by 801 · see citing works

Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

Hegi, M. E., Diserens, A., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 782 · see citing works

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 776 · see citing works

Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice

Wang, R.-H., Sengupta, K., Li, C., Kim, H., Cao, L., Xiao, C., Kim, S., Xu, X., Yin, Z., Chilton, B. S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.09.001 · Cited by 769 · see citing works

Platinum Resistance: The Role of DNA Repair Pathways

Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 754 · see citing works

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 749 · see citing works

DNA damage-induced G2–M checkpoint activation by histone H2AX and 53BP1

Fernández-Capetillo, Ó., Chen, H. T., Celeste, A., Ward, I. M., Romanienko, P. J., Morales, J. C., Naka, K., Xia, Z., Camerini‐Otero, R. D., Motoyama, N., et al. (2002) · Nature Cell Biology · doi:10.1038/ncb884 · Cited by 644 · see citing works

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 630 · see citing works

Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining

Miller, K. M., Tjeertes, J. V., Coates, J., Legube, G., Polo, S. E., Britton, S., & Jackson, S. P. (2010) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.1899 · Cited by 629 · see citing works

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

Farmer, P. J., Bonnefoi, H. R., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M. J., Campone, M., Brain, E. G. C., et al. (2009) · Nature Medicine · doi:10.1038/nm.1908 · Cited by 618 · see citing works

PALB2 is an integral component of the BRCA complex required for homologous recombination repair

Sy, S. M.-H., Huen, M. S. Y., & Chen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811159106 · Cited by 607 · see citing works

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · see citing works

p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA Damage

Reinhardt, H. C., Aslanian, A., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 594 · see citing works

53BP1, a Mediator of the DNA Damage Checkpoint

Wang, B., Matsuoka, S., Carpenter, P. B., & Elledge, S. J. (2002) · Science · doi:10.1126/science.1076182 · Cited by 578 · see citing works

Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

Norquist, B. M., Wurz, K., Pennil, C. C., Garcia, R. L., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577 · see citing works

PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response

Zhang, F., Ma, J., Wu, J., Ye, L., Cai, H., Xia, B., & Yu, X. (2009) · Current Biology · doi:10.1016/j.cub.2009.02.018 · Cited by 556 · see citing works

Principles of ubiquitin and SUMO modifications in DNA repair

Bergink, S., & Jentsch, S. (2009) · Nature · doi:10.1038/nature07963 · Cited by 525 · see citing works

Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cellsPreprint

Pierce, A. J., Hu, P., Han, M., Ellis, N. A., & Jasin, M. (2001) · Genes & Development · doi:10.1101/gad.946401 · Cited by 514 · see citing works

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487 · see citing works

Aberrant cell cycle checkpoint function and early embryonic death in Chk1−/− micePreprint

Takai, H., Tominaga, K., Motoyama, N., Minamishima, Y. A., Nagahama, H., Tsukiyama, T., Ikeda, K., Nakayama, K., Nakanishi, M., & Nakayama, K. (2000) · Genes & Development · doi:10.1101/gad.14.12.1439 · Cited by 478 · see citing works

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer

Liu, X., Holstege, H. H., van der Gulden, H. M. L., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 474 · see citing works

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2

Xia, B., Dorsman, J. C., Ameziane, N., de Vries, Y., Rooimans, M. A., Sheng, Q., Pals, G., Errami, A., Gluckman, E., Llera, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1942 · Cited by 465 · see citing works

Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance

Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N. D., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457 · see citing works

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53

Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453 · see citing works

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yuluğ, I. G., Merlano, M. C., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 445 · see citing works

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM

Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 442 · see citing works

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

Dai, Y., & Grant, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1029 · Cited by 438 · see citing works

Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription

Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 435 · see citing works

Genetic Interactions in Cancer Progression and Treatment

Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 421 · see citing works

Chemosensitivity linked to p73 function

Irwin, M. S., Kondo, K., Marín, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 406 · see citing works

53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer

DiTullio, R. A., Mochan, T. A., Venere, M., Bártková, J., Sehested, M., Bártek, J., & Halazonetis, T. D. (2002) · Nature Cell Biology · doi:10.1038/ncb892 · Cited by 399 · see citing works

BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ

Litman, R., Peng, M., Jin, Z., Zhang, F., Zhang, J., Powell, S., Andreassen, P. R., & Cantor, S. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.004 · Cited by 396 · see citing works

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382 · see citing works

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works

Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control

Bhaskara, S., Chyla, B., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 369 · see citing works

Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis

Wang, R.-H., Yin, Z., Kim, H., Xu, X., Cao, L., Lahusen, T. J., Lee, M., Xiao, C., Vassilopoulos, A., Chen, W., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.09.011 · Cited by 361 · see citing works

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G. B., Pires, M. M., Maurer, M., Holm, K., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 357 · see citing works

Hdac3 is essential for the maintenance of chromatin structure and genome stability

Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353 · see citing works

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H. M., Odijk, H., Zelensky, A. N., Chris van, B. R. E. E., Stalpers, L. J. A., Buist, M. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101053108 · Cited by 353 · see citing works

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H. H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 336 · see citing works

A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers

Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., et al. (2011) · Nature · doi:10.1038/nature10155 · Cited by 333 · see citing works

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 326 · see citing works

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma

Sakai, W., Swisher, E. M., Jacquemont, C. F., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 322 · see citing works

A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency

Cao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R.-H., Cao, L. L., Wu, J. J., Peng, T.-N., Chen, J., Nussenzweig, A., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.037 · Cited by 308 · see citing works

Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors

Shafee, N., Smith, C. R., Wei, S., Kim, Y. H., Mills, G. B., Hortobágyi, G. N., Stanbridge, E. J., & Lee, E. Y.-H. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5480 · Cited by 305 · see citing works

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G. A., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 303 · see citing works

The combined status of ATM and p53 link tumor development with therapeutic responsePreprint

Jiang, H., Reinhardt, H. C., Bártková, J., Tommiska, J., BLOMQVIST, C. P., Nevanlinna, H. A., Bártek, J., Yaffe, M. B., & Hemann, M. T. (2009) · Genes & Development · doi:10.1101/gad.1815309 · Cited by 303 · see citing works

PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2

Zhang, F., Fan, Q., Ren, K., & Andreassen, P. R. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0123 · Cited by 303 · see citing works

Topoisomerase levels determine chemotherapy response in vitro and in vivo

Burgess, D. J., Doles, J. D., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803513105 · Cited by 302 · see citing works

Preventing Nonhomologous End Joining Suppresses DNA Repair Defects of Fanconi Anemia

Adamo, A., Collis, S. J., Adelman, C. A., Silva, N., Hořejšı́, Z., Ward, J. D., Martínez-Pérez, E., Boulton, S. J., & Volpe, A. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.026 · Cited by 297 · see citing works

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

Mir, S. E., Hamer, P. C. D. W., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294 · see citing works

Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Zhou, W., Gurubhagavatula, S., Liu, G., Park, S., Neuberg, D. S., Wain, J. C., Lynch, T. J., Li, S., & Christiani, D. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0247 · Cited by 291 · see citing works

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

Johnson, N., Li, Y., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290 · see citing works

Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator

Ishida, S., McCormick, F. P., Smith‐McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 290 · see citing works

SIRT1 Regulates the Function of the Nijmegen Breakage Syndrome Protein

Yuan, Z., Zhang, X. M., Sengupta, N., Lane, W. S., & Seto, E. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.029 · Cited by 271 · see citing works

Stage-specific sensitivity to p53 restoration during lung cancer progression

Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Rivera, F. J. S., Resnick, R., Bronson, R. T., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 271 · see citing works

BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance

Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C. N., van der Heijden, I., van der Gulden, H. M. L., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 261 · see citing works

Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.

Wessels, L. F. A., van Welsem, T., Hart, A. A. M., Veer, L. J. V., Reinders, M. J. T., & Nederlof, P. M. (2002) · PubMed · Cited by 252 · see citing works

Selective activation of p53-mediated tumour suppression in high-grade tumours

Junttila, M. R., Karnezis, A. N., Garcia, D. A., Madriles, F., Kortlever, R. M., Rostker, F., Swigart, L. B., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 244 · see citing works

Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells

Fattah, F. J., Lee, E. H., Weisensel, N. A., Wang, Y., Lichter, N., & Hendrickson, E. A. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000855 · Cited by 244 · see citing works

BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity

Shakya, R., Reid, L. J., Reczek, C. R., Cole, F., Egli, D., Lin, C.-S., deRooij, D. G., Hirsch, S., Ravi, K., Hicks, J. B., et al. (2011) · Science · doi:10.1126/science.1209909 · Cited by 244 · see citing works

Ku70 Corrupts DNA Repair in the Absence of the Fanconi Anemia Pathway

Pace, P., Mosedale, G., Hodskinson, M. R. G., Rosado, I. V., Sivasubramaniam, M., & Patel, K. J. (2010) · Science · doi:10.1126/science.1192277 · Cited by 239 · see citing works

Loss of ATM/Chk2/p53 Pathway Components Accelerates Tumor Development and Contributes to Radiation Resistance in Gliomas

Squatrito, M., Brennan, C., Helmy, K. Y., Huse, J. T., Petrini, J. H. J., & Holland, E. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.034 · Cited by 238 · see citing works

Somatic Mosaicism in Fanconi Anemia: Molecular Basis and Clinical Significance

Foe, J. R. L. T., Kwee, M. L., Rooimans, M. A., Oostra, A. B., Veerman, A. J. P., van Weel, M., Pauli, R. M., Shahidi, N., Dokal, I. S., Roberts, I. E., et al. (1997) · European Journal of Human Genetics · doi:10.1159/000484749 · Cited by 238 · see citing works

Distinct Roles of Chromatin-Associated Proteins MDC1 and 53BP1 in Mammalian Double-Strand Break Repair

Xie, A., Hartlerode, A. J., Stucki, M., Odate, S., Puget, N., Kwok, A., Nagaraju, G., Yan, C. T., Alt, F. W., Chen, J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.12.005 · Cited by 232 · see citing works

DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization

Reinhardt, H. C., Hasskamp, P., Schmedding, I., Morandell, S., van Vugt, M. A. T. M., Wang, X., Linding, R., Ong, S., Weaver, D. T., Carr, S. A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.018 · Cited by 229 · see citing works

ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer

Viguier, J., Boige, V., Miquel, C., Pocard, M. D., Giraudeau, B., Sabourin, J., Ducreux, M. P., Sarasin, A. R., & Praz, F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2216 · Cited by 226 · see citing works

Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.

David, Y. B., Chetrit, A., Hirsh-Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben-Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.463 · Cited by 224 · see citing works

SIRT1 Regulates UV-Induced DNA Repair through Deacetylating XPA

Fan, W., & Luo, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.006 · Cited by 223 · see citing works

Error-prone translesion synthesis mediates acquired chemoresistance

Xie, K., Doles, J. D., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 222 · see citing works

A DNA Damage Response Screen Identifies RHINO, a 9-1-1 and TopBP1 Interacting Protein Required for ATR Signaling

Cotta‐Ramusino, C., McDonald, E. R., Hurov, K. E., Sowa, M. E., Harper, J. W., & Elledge, S. J. (2011) · Science · doi:10.1126/science.1203430 · Cited by 221 · see citing works

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.Preprint

Oliver, T., Mercer, K. L., Sayles, L., Burke, J., Mendus, D., Lovejoy, K. S., Cheng, M., Subramanian, A., Mu, D., Powers, S., et al. (2010) · Genes & Development · doi:10.1101/gad.1897010 · Cited by 220 · see citing works

Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism

Waisfisz, Q., Morgan, N. V., Savino, M., de Winter, J. P., van Berkel, C. G. M., Hoatlin, M. E., Ianzano, L., Gibson, R. A., Arwert, F., Savoia, A., et al. (1999) · Nature Genetics · doi:10.1038/11956 · Cited by 208 · see citing works

Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair

Bryant, H. E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl108 · Cited by 208 · see citing works

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Schmidt, M. K., van Beers, E. H., Cornelissen, S., Holtkamp, M., Froklage, F. E., de Vries, E. G. E., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq624 · Cited by 198 · see citing works

Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy

Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190 · see citing works

Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response

Kao, G. D., McKenna, W. G., Guenther, M. G., Muschel, R. J., Lazar, M. A., & Yen, T. J. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200209065 · Cited by 178 · see citing works

SIRT1 deacetylates APE1 and regulates cellular base excision repair

Yamamori, T., DeRicco, J. S., Naqvi, A., Hoffman, T. A., Mattagajasingh, I., Kasuno, K., Jung, S.-B., Kim, C., & Irani, K. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1039 · Cited by 176 · see citing works

Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional Assays

Lee, M. S., Green, R., Marsillac, S. M., Coquelle, N., Williams, R. S., Yeung, T., Foo, D., Hau, D., Hui, B., Monteiro, Á. N. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4563 · Cited by 170 · see citing works

Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model

Bric, A., Miething, C., Bialucha, C. U., Scuoppo, C., Zender, L., Krasnitz, A., Xuan, Z., Zuber, J. A., Wigler, M. H., Hicks, J. B., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.015 · Cited by 160 · see citing works

Nucleotide Excision Repair- and Polymerase η-Mediated Error-Prone Removal of Mitomycin C Interstrand Cross-Links

Zheng, H., Wang, X., Warren, A. J., Legerski, R. J., Nairn, R. S., Hamilton, J. W., & Li, L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.754-761.2003 · Cited by 149 · see citing works

Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C

Ming, M., Shea, C. R., Guo, X., Li, X., Soltani, K., Han, W., & He, Y.-Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010377108 · Cited by 145 · see citing works

Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2

Kuznetsov, S. G., Liu, P., & Sharan, S. K. (2008) · Nature Medicine · doi:10.1038/nm.1719 · Cited by 139 · see citing works

Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage

Johnson, N., Cai, D. D., Kennedy, R. D., Pathania, S., Arora, M., Li, Y.-C., D’Andrea, A. D., Parvin, J. D., & Shapiro, G. I. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.036 · Cited by 138 · see citing works

In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression

Meacham, C. E., Ho, E. E., Dubrovsky, E., Gertler, F. B., & Hemann, M. T. (2009) · Nature Genetics · doi:10.1038/ng.451 · Cited by 127 · see citing works

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

David, Y. B., Chetrit, A., Hirsh‐Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben‐Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.2.463 · Cited by 126 · see citing works

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

Postel-Vinay, S. C., Vanhecke, E., Olaussen, K. A., Lord, C. J., Ashworth, A., & Soria, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.3 · Cited by 113 · see citing works

6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance

Issaeva, N., Thomas, H. D., Djurenovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S., Pedley, N., Gottipati, P., Zur, R., Sleeth, K. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3416 · Cited by 104 · see citing works

Identification of BRCA1-IRIS, a BRCA1 locus product

ElShamy, W. M., & Livingston, D. M. (2004) · Nature Cell Biology · doi:10.1038/ncb1171 · Cited by 97 · see citing works

The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links

Al-Minawi, A. Z., Lee, Y.-F., Hakansson, D., Johansson, F., Lundin, C., Saleh-Gohari, N., Schultz, N. D., Jenssen, D., Bryant, H. E., Meuth, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp705 · Cited by 93 · see citing works

Limiting the Persistence of a Chromosome Break Diminishes Its Mutagenic Potential

Bennardo, N., Gunn, A., Cheng, A., Hasty, P., & Stark, J. M. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000683 · Cited by 88 · see citing works

A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors

Evers, B., Schut, E., van der Burg, E., Braumuller, T. M., Egan, D. A., Holstege, H. H., Edser, P. A. H., Adams, D. J., Wade‐Martins, R., Bouwman, P., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2434 · Cited by 78 · see citing works

A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance

Menzel, T., Nähse, V., Kousholt, A. N., Klein, D. K., Lund‐Andersen, C., Lees, M. J., Johansen, J. V., Syljuåsen, R. G., & Sørensen, C. S. (2011) · EMBO Reports · doi:10.1038/embor.2011.99 · Cited by 75 · see citing works

Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations

Chang, S., Biswas, K., Martin, B. K., Stauffer, S., & Sharan, S. K. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39836 · Cited by 72 · see citing works

Allele-specific tumor spectrum in Pten knockin mice

Wang, H., Karikomi, M., Naidu, S. K., Rajmohan, R., Caserta, E., Chen, H., Rawahneh, M., Moffitt, J., Stephens, J. A., Fernández, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912524107 · Cited by 66 · see citing works

A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1

Drost, M., Zonneveld, J. B. M., van Dijk, L., Morreau, H. M., Tops, C. M. J., Vasen, H. F. A., Wijnen, J., & de Wind, N. (2009) · Human Mutation · doi:10.1002/humu.21180 · Cited by 65 · see citing works

Do predictive signatures really predict response to cancer chemotherapy?

Borst, P., & Wessels, L. F. A. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14326 · Cited by 64 · see citing works

Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo

Niida, H., Murata, K., Shimada, M., Ogawa, K., Ohta, K., Suzuki, K., Fujigaki, H., Khaw, A. K., Banerjee, B., Hande, M. P., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.218 · Cited by 56 · see citing works

Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.

Ikeda, H., Matsushita, M., Waisfisz, Q., Kinoshita, A., Oostra, A. B., Nieuwint, A. W. M., de Winter, J. P., Hoatlin, M. E., Kawai, Y., Sasaki, M. S., et al. (2003) · PubMed · Cited by 55 · see citing works

Targeting Base Excision Repair for Chemosensitization

Adhikari, S., Choudhury, S., Mitra, P. S., Dubash, J., Sajankila, S. P., & Roy, R. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008784220366 · Cited by 49 · see citing works

A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants

Drost, M., Zonneveld, J. B. M., van Hees‐Stuivenberg, S., Rasmussen, L. J., Hofstra, R. M. W., & de Wind, N. (2011) · Human Mutation · doi:10.1002/humu.22000 · Cited by 48 · see citing works

BRCA1-IRIS Overexpression Promotes Cisplatin Resistance in Ovarian Cancer Cells

Chock, K. L., Allison, J. M., Shimizu, Y., & ElShamy, W. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1352 · Cited by 38 · see citing works

Targeted Radiosensitization of Cells Expressing Truncated DNA Polymerase β

Neijenhuis, S., Verwijs-Janssen, M., van den Broek, L. J., Begg, A. C., & Vens, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3901 · Cited by 34 · see citing works

Drug candidates derailed in case of mistaken identity

Ledford, H. K. (2012) · Nature · doi:10.1038/483519a · Cited by 28 · see citing works

High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?

Nieto, Y. L., & Shpall, E. J. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328324f48b · Cited by 28 · see citing works

Melphalan as a treatment for BRCA -related ovarian carcinoma: can you teach an old drug new tricks?: Figure 1

Osher, D. J., Kushner, Y. B., Arseneau, J., & Foulkes, W. D. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.086405 · Cited by 22 · see citing works

Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1

Pettigrew, C. A., French, J. D., Saunus, J. M., Edwards, S. L., Sauer, A. V., Smart, C. E., Lundström, T., Wiesner, C., Spurdle, A. B., Rothnagel, J. A., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0256-2 · Cited by 18 · see citing works

Cancer drug resistance: an evolving paradigm

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · see citing works

Mechanisms of DNA damage, repair, and mutagenesis

Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039 · see citing works

DNA Damage Sensing by the ATM and ATR Kinases

Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514 · see citing works

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,017 · see citing works

Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells

Zellweger, R., Dalcher, D., Mutreja, K., Berti, M., Schmid, J. A., Herrador, R., Vindigni, A., & Lopes, M. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201406099 · Cited by 660 · see citing works

Therapeutic opportunities within the DNA damage response

Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587 · see citing works

AIE Luminogens for Bioimaging and Theranostics: From Organelles to Animals

Qian, J., & Tang, B. Z. (2017) · Chem · doi:10.1016/j.chempr.2017.05.010 · Cited by 576 · see citing works

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M., Zhou, Y., Serebriiskii, I. G., Slifker, M. J., Alpaugh, K. R., Dulaimi, E., Palma, N. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 521 · see citing works

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 521 · see citing works

DNA repair pathways and cisplatin resistance: an intimate relationship

Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 450 · see citing works

Cancer stem cells and chemoresistance: The smartest survives the raid

Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 433 · see citing works

New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment

Chen, S., & Chang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 432 · see citing works

Machine learning approaches to drug response prediction: challenges and recent progress

Adam, G. A., Rampášek, L., Safikhani, Z., Smirnov, P., Haibe‐Kains, B., & Goldenberg, A. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0122-1 · Cited by 427 · see citing works

Molecular aspects of cancer cell resistance to chemotherapy

Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 409 · see citing works

DNA Damage/Repair Management in Cancers

Alhmoud, J. F., Woolley, J. F., Moustafa, A. A., & Malki, M. I. (2020) · Cancers · doi:10.3390/cancers12041050 · Cited by 378 · see citing works

Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor

Yin, Q., Shen, J., Zhang, Z., Yu, H., & Li, Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.04.011 · Cited by 366 · see citing works

DNA helicases involved in DNA repair and their roles in cancer

Brosh, R. M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3560 · Cited by 345 · see citing works

Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer

Quereda, V., Bayle, S., Vena, F., Frydman, S. M., Monastyrskyi, A., Roush, W. R., & Duckett, D. R. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.004 · Cited by 352 · see citing works

A Forward Vision for Chemodynamic Therapy: Issues and Opportunities

Zhao, P., Li, H., & Bu, W. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202210415 · Cited by 338 · see citing works

Drug resistance in cancer: mechanisms and tackling strategies

Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 312 · see citing works

Targeting DNA damage response in cancer therapy

Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 295 · see citing works

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 282 · see citing works

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G. S., Brown, J., Lau, A., Pratt, G., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 281 · see citing works

Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers

Avril, T., Vauléon, É., & Chevet, É. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.72 · Cited by 274 · see citing works

Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress

Yan, S., Sorrell, M., & Berman, Z. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1666-4 · Cited by 247 · see citing works

Organelle-specific initiation of cell death

Galluzzi, L., Bravo-San Pedro, J. M., & Kroemer, G. (2014) · Nature Cell Biology · doi:10.1038/ncb3005 · Cited by 239 · see citing works

Targeting tumour-supportive cellular machineries in anticancer drug development

Dobbelstein, M., & Moll, U. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229 · see citing works

The mechanism(s) of action of antioxidants: From scavenging reactive oxygen/nitrogen species to redox signaling and the generation of bioactive secondary metabolites

Hunyadi, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21592 · Cited by 229 · see citing works

Clinical cancer genomic profiling

Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 227 · see citing works

Selective Autophagy Regulates Cell Cycle in Cancer Therapy

Zheng, K., He, Z., Kitazato, K., & Wang, Y. (2018) · Theranostics · doi:10.7150/thno.30308 · Cited by 226 · see citing works

Temozolomide-associated hypermutation in gliomas

Choi, S., Yu, Y., Grimmer, M., Wahl, M. T., Chang, S. M., & Costello, J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy016 · Cited by 216 · see citing works

Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer

Liu, H., Liu, Y., Yang, F., Zhang, L., Zhang, F., Hu, X., Shao, Z., & Li, D. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa130 · Cited by 205 · see citing works

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Wengner, A. M., Siemeister, G., Lücking, U., Lefranc, J., Wortmann, L., Lienau, P., Bader, B., Bömer, U., Moosmayer, D., Eberspächer, U., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0019 · Cited by 211 · see citing works

Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation

Gasparini, P., Lovat, F., Fassan, M., Casadei, L., Cascione, L., Jacob, N. K., Carasi, S., Palmieri, D., Costinean, S., Shapiro, C. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402604111 · Cited by 210 · see citing works

ATM signalling and cancer

Cremona, C. A., & Behrens, A. (2013) · Oncogene · doi:10.1038/onc.2013.275 · Cited by 206 · see citing works

Therapeutic strategies to overcome cisplatin resistance in ovarian cancer

Song, M., Cui, M., & Liu, K. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114205 · Cited by 207 · see citing works

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?

Szumilak, M., Wiktorowska‐Owczarek, A., & Stańczak, A. (2021) · Molecules · doi:10.3390/molecules26092601 · Cited by 212 · see citing works

Interplay between Fanconi anemia and homologous recombination pathways in genome integrity

Michl, J., Zimmer, J., & Tarsounas, M. (2016) · The EMBO Journal · doi:10.15252/embj.201693860 · Cited by 204 · see citing works

Organelle-Specific Initiation of Autophagy

Sica, V., Galluzzi, L., Bravo-San Pedro, J. M., Izzo, V., Maiuri, M. C., & Kroemer, G. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.021 · Cited by 205 · see citing works

DNA damage tolerance: a double-edged sword guarding the genome.

Ghosal, G., & Chen, J. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.04.01 · Cited by 204 · see citing works

Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view

Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188 · see citing works

Harnessing DNA Double-Strand Break Repair for Cancer Treatment

Trenner, A., & Sartori, A. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01388 · Cited by 190 · see citing works

USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy

García‐Santisteban, I., Peters, G. J., Giovannetti, E., & Rodríguez, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-91 · Cited by 191 · see citing works

Deep Insight of Design, Mechanism, and Cancer Theranostic Strategy of Nanozymes

Yang, L. G., Dong, S., Gai, S., Yang, D., Ding, H., Feng, L., Yang, G., Rehman, Z., & Yang, P. (2023) · Nano-Micro Letters · doi:10.1007/s40820-023-01224-0 · Cited by 190 · see citing works

Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy

Liu, T., Wan, Y., Xiao, Y., Xia, C., & Duan, G. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00491 · Cited by 180 · see citing works

Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients

Gruosso, T., Mieulet, V., Cardon, M., Bourachot, B., Kieffer, Y., Devun, F., Dubois, T., Dutreix, M., Vincent‐Salomon, A., Miller, K. M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505891 · Cited by 179 · see citing works

Cancer drug resistance: redox resetting renders a way

Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 179 · see citing works

Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics

Tsai, C.-F., Wang, Y.-T., Yen, H., Tsou, C., Ku, W., Lin, P.-Y., Chen, H., Nesvizhskii, A. I., Ishihama, Y., & Chen, Y. (2015) · Nature Communications · doi:10.1038/ncomms7622 · Cited by 173 · see citing works

Genomic landscape of DNA repair genes in cancer

Chae, Y. K., Anker, J. F., Carneiro, B. A., Chandra, S., Kaplan, J. B., Kalyan, A., Santa-Maria, C. A., Platanias, L. C., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8196 · Cited by 167 · see citing works

Identifying the target genes of SUPPRESSOR OF GAMMA RESPONSE 1, a master transcription factor controlling DNA damage response in Arabidopsis

Ogita, N., Okushima, Y., Tokizawa, M., Yamamoto, Y. Y., Tanaka, M., Seki, M., Makita, Y., Matsui, M., Yoshiyama, K., Sakamoto, T., et al. (2018) · The Plant Journal · doi:10.1111/tpj.13866 · Cited by 158 · see citing works

Clonal evolution in hematological malignancies and therapeutic implications

Landau, D. A., Carter, S. L., Getz, G. A., & Wu, C. J. (2013) · Leukemia · doi:10.1038/leu.2013.248 · Cited by 168 · see citing works

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy

Xu, Y., & Her, C. (2015) · Biomolecules · doi:10.3390/biom5031652 · Cited by 164 · see citing works

Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment

Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W. M., O’Connor, M. J., Vrieling, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0571 · Cited by 162 · see citing works

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?

Bouwman, P., & Jonkers, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 162 · see citing works

A polydopamine-based platform for anti-cancer drug delivery

Ambekar, R. S., & Kandasubramanian, B. (2019) · Biomaterials Science · doi:10.1039/c8bm01642a · Cited by 159 · see citing works

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Ha, K., Fiskus, W. C., Choi, D. S., Bhaskara, S., Cerchietti, L. C. A., Devaraj, S. G. T., Shah, B., Sharma, S., Chang, J. C., Melnick, A. M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2154 · Cited by 157 · see citing works

DNA damage response and resistance of cancer stem cells

Abad, E., Graifer, D., & Lyakhovich, A. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.008 · Cited by 148 · see citing works

Oncogenic MicroRNAs: Key Players in Malignant Transformation

Frixa, T., Donzelli, S., & Blandino, G. (2015) · Cancers · doi:10.3390/cancers7040904 · Cited by 149 · see citing works

Cancer chemoresistance; biochemical and molecular aspects: a brief overview

Kachalaki, S., Ebrahimi, M., Khosroshahi, L. M., Mohammadinejad, S., & Baradaran, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.025 · Cited by 146 · see citing works

A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance

Wang, Z., Xu, Z., & Zhu, G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608936 · Cited by 140 · see citing works

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Wang, S., Liu, X., Chen, S., Liu, Z., Zhang, X., Liang, X., & Li, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05639 · Cited by 140 · see citing works

MIR34Aregulates autophagy and apoptosis by targetingHMGB1in the retinoblastoma cell

Liu, K., Huang, J. X., Xie, M., Yu, Y. H., Zhu, S., Kang, R., Cao, L., Tang, D., & Duan, X. (2014) · Autophagy · doi:10.4161/auto.27418 · Cited by 135 · see citing works

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons

Funt, S. A., & Rosenberg, J. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.188 · Cited by 134 · see citing works

Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux

Wang, K., Zhang, T., Lei, Y., Li, X., Jiang, J., Lan, J., Liu, Y., Chen, H., Gao, W., Xie, N., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1409405 · Cited by 134 · see citing works

The interplay between DNA repair and autophagy in cancer therapy

Zhang, D., Tang, B., Xie, X., Xiao, Y., Yang, S., & Zhang, J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1046022 · Cited by 131 · see citing works

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy

Yang, R., Li, Y., Wang, H., Qin, T., Yin, X., & Ma, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00071-6 · Cited by 134 · see citing works

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic

Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 127 · see citing works

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma

Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126 · see citing works

The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance

Hekmatshoar, Y., Nakhle, J., Galloni, M., & Vignais, M. (2018) · Biochemical Journal · doi:10.1042/bcj20170712 · Cited by 124 · see citing works

Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway

Xia, Y., He, Z., Liu, B., Wang, P., & CHEN, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3897 · Cited by 122 · see citing works

Mesoporous Magnetic Gold “Nanoclusters” as Theranostic Carrier for Chemo-Photothermal Co-therapy of Breast Cancer

Peng, J., Qi, T., Liao, J., Chu, B., Yang, Q., Qu, Y., Li, W., Li, H., Luo, F., & Qian, Z. (2014) · Theranostics · doi:10.7150/thno.7869 · Cited by 119 · see citing works

Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer

Bisso, A., Faleschini, M., Zampa, F., Capaci, V., Santa, J. D., Santarpia, L., Piazza, S., Cappelletti, V., Daidone, M. G., Agami, R., et al. (2013) · Cell Cycle · doi:10.4161/cc.24757 · Cited by 118 · see citing works

Therapeutic landscape in mutational triple negative breast cancer

Shi, Y., Jin, J., Ji, W., & Guan, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0850-9 · Cited by 118 · see citing works

Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2

Carter, M., Jemth, A., Hagenkort, A., Page, B. D. G., Gustafsson, R., Griese, J. J., Gad, H., Valerie, N. C. K., Desroses, M., Boström, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8871 · Cited by 116 · see citing works

Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance

Michelena, J., Lezaja, A., Teloni, F., Schmid, T., Imhof, R., & Altmeyer, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05031-9 · Cited by 115 · see citing works

The DNA Damage Response and Inflammation in Cancer

Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 110 · see citing works

A dual-responsive, hyaluronic acid targeted drug delivery system based on hollow mesoporous silica nanoparticles for cancer therapy

Huang, L., Liu, J., Gao, F., Cheng, Q., Lü, B., Zheng, H. S., Xu, H., Xu, P., Zhang, X., & Zeng, X. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00989a · Cited by 107 · see citing works

Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance

Xiao, W., Song, M., Li, W., Huang, J., Yang, G. Y., & Wang, Y. (2021) · Theranostics · doi:10.7150/thno.59342 · Cited by 108 · see citing works

CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells

Kumar, S., Zeng, Z., Bagati, A., Tay, R. E., Sanz, L. A., Hartono, S. R., Ito, Y., Abderazzaq, F. O., Hatchi, E., Jiang, P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1144 · Cited by 101 · see citing works

MicroRNA-21: a therapeutic target for reversing drug resistance in cancer

Hong, L., Han, Y., Zhang, Y., Zhang, H., Zhao, Q., Wu, K., & Fan, D. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.819853 · Cited by 103 · see citing works

MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer

Chen, S., Wu, J., Jiao, K., Wu, Q., Ma, J., Chen, D., Kang, J., Zhao, G., Shi, Y., Fan, D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0950-x · Cited by 100 · see citing works

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer

Górecki, L., Andrš, M., & Korábečný, J. (2021) · Cancers · doi:10.3390/cancers13040795 · Cited by 99 · see citing works

Prolyl Isomerase PIN1 Regulates DNA Double-Strand Break Repair by Counteracting DNA End Resection

Steger, M., Murina, O., Hühn, D., Ferretti, L. P., Walser, R., Hänggi, K., Lafranchi, L., Neugebauer, C., Paliwal, S., Janščák, P., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.03.023 · Cited by 98 · see citing works

A New View of Pathway-Driven Drug Resistance in Tumor Proliferation

Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 93 · see citing works

Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor

Hotchkiss, K. M., & Sampson, J. H. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03598-2 · Cited by 91 · see citing works

Deubiquitylating Enzymes and DNA Damage Response Pathways

Jacq, X., Kemp, M. I., Martin, N. M. B., & Jackson, S. P. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9635-3 · Cited by 90 · see citing works

Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer

Costea, T., Vlad, O., Miclea, L. C., Ganea, C., Szöllõsi, J., & Mocanu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020401 · Cited by 92 · see citing works

DNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies

Wang, Q. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.57 · Cited by 91 · see citing works

A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy

Liu, C., Srihari, S., Cao, K. L., Chenevix‐Trench, G., Simpson, P. T., Ragan, M. A., & Khanna, K. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku284 · Cited by 88 · see citing works

microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview

Gabra, M., & Salmena, L. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00255 · Cited by 89 · see citing works

Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer

Yang, H., Tang, C., & Yin, C. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.04.020 · Cited by 89 · see citing works

Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells

Bindra, R. S., Goglia, A. G., Jasin, M., & Powell, S. N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt255 · Cited by 88 · see citing works

Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property

Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-13232-3 · Cited by 84 · see citing works

The paradigm of drug resistance in cancer: an epigenetic perspective

Adhikari, S., Bhattacharya, A., Adhikary, S., Singh, V., Gadad, S. S., Roy, S., & Das, C. (2022) · Bioscience Reports · doi:10.1042/bsr20211812 · Cited by 88 · see citing works

Double‐strand DNA break repair: molecular mechanisms and therapeutic targets

Tan, J., Sun, X., Zhao, H., Guan, H., Gao, S., & Zhou, P. (2023) · MedComm · doi:10.1002/mco2.388 · Cited by 96 · see citing works

Actionable gene-based classification toward precision medicine in gastric cancer

Ichikawa, H., Nagahashi, M., Shimada, Y., Hanyu, T., Ishikawa, T., Kameyama, H., Kobayashi, T., Sakata, J., Yabusaki, H., Nakagawa, S., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0484-3 · Cited by 87 · see citing works

Tumour microenvironment-responsive semiconducting polymer-based self-assembling nanotheranostics

Yáng, Z., Dai, Y., Shan, L., Shen, Z., Wang, Z., Yung, B. C., Jacobson, O., Liu, Y., Tang, W., Wang, S., et al. (2018) · Nanoscale Horizons · doi:10.1039/c8nh00307f · Cited by 87 · see citing works

DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes

Santarpia, L., Iwamoto, T., Leo, A. D., Hayashi, N., Bottai, G., Stampfer, M. R., André, F., Turner, N. C., Symmans, W. F., Hortobágyi, G. N., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0163 · Cited by 87 · see citing works

Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors

Pitts, T. M., Davis, S. L., Eckhardt, S. G., & Bradshaw‐Pierce, E. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.010 · Cited by 86 · see citing works

A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance

Li, F., Sun, H., Ren, J., Zhang, B., Hu, X., Fang, C., Lee, J., Gu, H., & Ling, D. (2022) · Nature Communications · doi:10.1038/s41467-022-35022-w · Cited by 85 · see citing works

DNA repair dysregulation from cancer driver to therapeutic target

Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051 · see citing works

DNA repair and the contribution to chemotherapy resistance

Nesic, K., Parker, P., Swisher, E. M., & Krais, J. J. (2025) · Genome Medicine · doi:10.1186/s13073-025-01488-8 · Cited by 50 · see citing works

Targeting DNA damage response in cancer therapy

Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 295 · see citing works

Targeting DNA damage response pathways in cancer

Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 870 · see citing works

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Liptay, M., Barbosa, J. S., & Rottenberg, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00670 · Cited by 29 · see citing works